Literature DB >> 2811384

Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate.

B N Gray1, M A Burton, D K Kelleher, J Anderson, P Klemp.   

Abstract

Ten patients with liver metastases from primary tumors in the colorectum were treated with selective internal radiation (SIR) therapy. This involved the embolisation of yttrium-90-containing microspheres into the hepatic artery at the time of laparotomy. The microspheres were concentrated in the microvasculature of the tumour nodules by the concurrent administration of angiotensin II. The radiation dose being delivered to liver parenchyma was measured at the time of operation by use of an intraoperative radiation detection probe. All nine patients in whom the preoperative carcinoembryonic antigen (CEA) level was elevated experienced a decrease in CEA levels posttreatment. Intraoperative dosimetry confirmed the poor correlation between total radioactivity used and radiation dose received by normal liver parenchyma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2811384     DOI: 10.1002/jso.2930420313

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  19 in total

1.  Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases.

Authors:  Maren Bienert; Barry McCook; Brian I Carr; David A Geller; Mike Sheetz; Nikhil Amesur; Norbert Avril
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06       Impact factor: 9.236

2.  Radioembolization of yttrium-90 microspheres for hepatic malignancy.

Authors:  Ravi Murthy; Paresh Kamat; Rodolfo Nuñez; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2008-03       Impact factor: 1.513

3.  Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Authors:  C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

Review 4.  Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases.

Authors:  Abdul Saied; Steven C Katz; N Joseph Espat
Journal:  Hepatobiliary Surg Nutr       Date:  2013-04       Impact factor: 7.293

5.  90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.

Authors:  Maren Bienert; Barry McCook; Brian I Carr; David A Geller; Mike Sheetz; Cecilia Tutor; Nikhil Amesur; Norbert Avril
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-17       Impact factor: 9.236

Review 6.  Liver metastases from colorectal cancer: radioembolization with systemic therapy.

Authors:  Nils H Nicolay; David P Berry; Ricky A Sharma
Journal:  Nat Rev Clin Oncol       Date:  2009-11-03       Impact factor: 66.675

Review 7.  Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.

Authors:  Andrew Kuei; Sammy Saab; Sung-Ki Cho; Stephen T Kee; Edward Wolfgang Lee
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

8.  Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases.

Authors:  R Cianni; C Urigo; E Notarianni; A Saltarelli; A D'Agostini; M Iozzino; T Dornbusch; E Cortesi
Journal:  Radiol Med       Date:  2010-01-20       Impact factor: 3.469

9.  Determination of tumour vascularity using selective hepatic angiography as compared with intrahepatic-arterial technetium-99m macroaggregated albumin scan in hepatocellular carcinoma.

Authors:  T W Leung; W Y Lau; S K Ho; M Chan; N W Leung; J Lin; C Metreweli; P J Johnson; A K Li
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 10.  Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.

Authors:  Eun Jeong Lee; Hyun Woo Chung; Joon-Hyung Jo; Young So
Journal:  Nucl Med Mol Imaging       Date:  2019-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.